Asthma Therapeutics Trends up to 2020 in Major Developed Markets 1

[email protected] Asthma Therapeutics Market Forecast up to 2020 in Major Developed Economies Summary: The analysis report includes complete market forecast up to 2020 for the major developed markets of North America, Europe and the Japan. It also discusses Asthma therapeutics in great detail with all the necessary pipeline analysis. Currently marketed products, treatment algorithm, clinical trial results, promising pipeline molecules, main drivers and barriers are also included in the report. The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025. Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest. Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in “Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations” Market Research Report at- http://www.marketreportsworld.com/asthmatherapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severeasthma-to-drive-market-growth-despite-patent-expirations-10070377 [phone] www.marketreportsworld.com [email protected]